<p>根据公司在最近向证券交易委员会的披露，LSV 资产管理公司在第三季度将其在 GoodRx Holdings, Inc.（NASDAQ:GDRX - 免费报告）的持股增加了 517.1%。该公司在此期间购买了额外的 1,973,017 股后，持有 2,354,581 股 GoodRx 的股票。根据其最近向证券交易委员会的备案，LSV 资产管理公司持有的 GoodRx 股份约占 0.68%，价值 996 万美元。</p>
<ul>
<li>Wegovy 与 Zepbound：谁赢得 GLP-1 药物之战？</li>
</ul>
<p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Cetera 投资顾问在第二季度购买了 GoodRx 的新股份，价值约为 50,000 美元。Walled Lake 规划与财富管理公司在第二季度购买了 GoodRx 的新股份，估值约为 55,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 GoodRx 的持仓增加了 202.3%。Tower Research Capital LLC TRC 现在拥有 11,327 股 GoodRx 的股票，价值 56,000 美元，此前在此期间又购买了 7,580 股。Bayesian Capital Management LP 在第二季度购买了 GoodRx 的新股份，价值约为 69,000 美元。最后，Lazard 资产管理公司在第二季度将其在 GoodRx 的股份增加了 43.6%。Lazard 资产管理公司现在拥有 17,142 股 GoodRx 的股票，价值 85,000 美元，此前在上个季度又收购了 5,201 股。目前，63.77% 的股票由机构投资者持有。</p>
<h2>GoodRx 股票表现</h2>
<p>GDRX 股票在周五开盘价为 2.18 美元。该公司的市值为 7.3996 亿美元，市盈率为 24.22，PEG 比率为 0.83，贝塔值为 1.50。该公司的 50 日简单移动平均线为 2.61 美元，200 日简单移动平均线为 3.39 美元。GoodRx Holdings, Inc.的年内最低价为 2.10 美元，年内最高价为 5.81 美元。该公司的债务与股本比率为 0.81，速动比率为 3.11，流动比率为 3.11。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>这只医疗股因增长 160% 而引发关注</li>
</ul>
<p>几位分析师最近对 GDRX 股票发表了看法。瑞穗证券在 11 月 6 日的研究报告中将 GoodRx 的目标价从 5.00 美元下调至 4.00 美元，并对该公司给予了 “中性” 评级。摩根大通在 11 月 11 日的报告中将 GoodRx 的目标价从 6.00 美元下调至 5.00 美元，并对该股票给予了 “增持” 评级。摩根士丹利在 12 月 18 日的研究报告中将 GoodRx 的目标价从 5.00 美元下调至 4.00 美元，并对该公司给予了 “持平” 评级。TD Cowen 在 11 月 10 日的研究报告中将 GoodRx 的目标价从 7.00 美元下调至 6.00 美元，并对该股票给予了 “买入” 评级。最后，巴克莱在 12 月 8 日的研究报告中开始覆盖 GoodRx，给予了 “减持” 评级，并设定了 3.00 美元的目标价。五位研究分析师对该股票给予了买入评级，七位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，GoodRx 目前的共识评级为 “持有”，平均目标价为 4.73 美元。</p>
<p><strong>阅读我们对 GDRX 的最新股票分析</strong></p>
<h2>GoodRx 简介</h2>
<p>（免费报告）</p>
<ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
<p>GoodRx Holdings, Inc. NASDAQ: GDRX 运营一个数字医疗平台，旨在帮助消费者比较美国零售药店的处方药价格。通过其网站和移动应用程序，GoodRx 汇总来自广泛药店网络的定价和折扣信息，使用户能够访问通用药物和品牌药物的优惠券和节省计划。该平台还提供价格透明工具，告知患者成本差异和可用折扣，以减轻处方药的经济负担。</p>
<p>除了其核心药物定价服务外，GoodRx 还在 GoodRx Care 品牌下提供远程医疗服务，为各种非紧急病症和处方需求提供虚拟咨询。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 GoodRx</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
<p><strong>想看看其他对冲基金持有的 GDRX 吗？</strong> 访问 HoldingsChannel.com 获取 GoodRx Holdings, Inc.（NASDAQ:GDRX - 免费报告）的最新 13F 备案和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
<p>在考虑 GoodRx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
<p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GDRX

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

美国医疗保健供应商 ETF - iShares

<p>LSV Asset Management 在第三季度将其在 GoodRx Holdings, Inc. (NASDAQ:GDRX) 的持股增加了 517.1%，目前持有 2,354,581 股，价值约 996 万美元。其他机构投资者也调整了他们的持仓，机构持有该股票的比例为 63.77%。GoodRx 的股票开盘价为 2.18 美元，市值为 7.3996 亿美元。分析师设定了不同的目标价格，普遍评级为 “持有”，平均目标价格为 4.73 美元。GoodRx 运营一个数字医疗平台，用于比较处方药价格</p>

<p>LSV Asset Management grew its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 517.1% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 2,354,581 shares of the company's stock after purchasing an additional 1,973,017 shares during the period. LSV Asset Management owned about 0.68% of GoodRx worth $9,960,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会的披露，LSV 资产管理公司在第三季度将其在 GoodRx Holdings, Inc.（NASDAQ:GDRX - 免费报告）的持股增加了 517.1%。该公司在此期间购买了额外的 1,973,017 股后，持有 2,354,581 股 GoodRx 的股票。根据其最近向证券交易委员会的备案，LSV 资产管理公司持有的 GoodRx 股份约占 0.68%，价值 996 万美元。</p>
</div><ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><ul>
<li>Wegovy 与 Zepbound：谁赢得 GLP-1 药物之战？</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Cetera Investment Advisers bought a new position in shares of GoodRx in the second quarter worth about $50,000. Walled Lake Planning &amp; Wealth Management LLC bought a new stake in GoodRx during the 2nd quarter valued at about $55,000. Tower Research Capital LLC TRC boosted its position in GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after buying an additional 7,580 shares during the period. Bayesian Capital Management LP bought a new position in GoodRx in the 2nd quarter worth about $69,000. Finally, Lazard Asset Management LLC grew its stake in GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after acquiring an additional 5,201 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Cetera 投资顾问在第二季度购买了 GoodRx 的新股份，价值约为 50,000 美元。Walled Lake 规划与财富管理公司在第二季度购买了 GoodRx 的新股份，估值约为 55,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 GoodRx 的持仓增加了 202.3%。Tower Research Capital LLC TRC 现在拥有 11,327 股 GoodRx 的股票，价值 56,000 美元，此前在此期间又购买了 7,580 股。Bayesian Capital Management LP 在第二季度购买了 GoodRx 的新股份，价值约为 69,000 美元。最后，Lazard 资产管理公司在第二季度将其在 GoodRx 的股份增加了 43.6%。Lazard 资产管理公司现在拥有 17,142 股 GoodRx 的股票，价值 85,000 美元，此前在上个季度又收购了 5,201 股。目前，63.77% 的股票由机构投资者持有。</p>
</div><h2>GoodRx Stock Performance</h2>
<div class="lb-trans"><h2>GoodRx 股票表现</h2>
</div><p>GDRX stock opened at $2.18 on Friday. The firm has a market cap of $739.96 million, a price-to-earnings ratio of 24.22, a PEG ratio of 0.83 and a beta of 1.50. The firm has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $3.39. GoodRx Holdings, Inc. has a one year low of $2.10 and a one year high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11.</p>
<div class="lb-trans"><p>GDRX 股票在周五开盘价为 2.18 美元。该公司的市值为 7.3996 亿美元，市盈率为 24.22，PEG 比率为 0.83，贝塔值为 1.50。该公司的 50 日简单移动平均线为 2.61 美元，200 日简单移动平均线为 3.39 美元。GoodRx Holdings, Inc.的年内最低价为 2.10 美元，年内最高价为 5.81 美元。该公司的债务与股本比率为 0.81，速动比率为 3.11，流动比率为 3.11。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>This healthcare stock making a buzz with 160% growth</li>
</ul>
<div class="lb-trans"><ul>
<li>这只医疗股因增长 160% 而引发关注</li>
</ul>
</div><p>Several analysts have recently weighed in on GDRX shares. Mizuho decreased their price target on shares of GoodRx from $5.00 to $4.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, November 6th. JPMorgan Chase &amp; Co. reduced their price objective on GoodRx from $6.00 to $5.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Morgan Stanley decreased their target price on GoodRx from $5.00 to $4.00 and set an &#34;equal weight&#34; rating for the company in a research report on Thursday, December 18th. TD Cowen dropped their price target on GoodRx from $7.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, November 10th. Finally, Barclays initiated coverage on GoodRx in a research note on Monday, December 8th. They set an &#34;underweight&#34; rating and a $3.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of &#34;Hold&#34; and an average target price of $4.73.</p>
<div class="lb-trans"><p>几位分析师最近对 GDRX 股票发表了看法。瑞穗证券在 11 月 6 日的研究报告中将 GoodRx 的目标价从 5.00 美元下调至 4.00 美元，并对该公司给予了 “中性” 评级。摩根大通在 11 月 11 日的报告中将 GoodRx 的目标价从 6.00 美元下调至 5.00 美元，并对该股票给予了 “增持” 评级。摩根士丹利在 12 月 18 日的研究报告中将 GoodRx 的目标价从 5.00 美元下调至 4.00 美元，并对该公司给予了 “持平” 评级。TD Cowen 在 11 月 10 日的研究报告中将 GoodRx 的目标价从 7.00 美元下调至 6.00 美元，并对该股票给予了 “买入” 评级。最后，巴克莱在 12 月 8 日的研究报告中开始覆盖 GoodRx，给予了 “减持” 评级，并设定了 3.00 美元的目标价。五位研究分析师对该股票给予了买入评级，七位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，GoodRx 目前的共识评级为 “持有”，平均目标价为 4.73 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on GDRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 GDRX 的最新股票分析</strong></p>
</div><h2>GoodRx Profile</h2>
<div class="lb-trans"><h2>GoodRx 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
</div><p>GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc. NASDAQ: GDRX 运营一个数字医疗平台，旨在帮助消费者比较美国零售药店的处方药价格。通过其网站和移动应用程序，GoodRx 汇总来自广泛药店网络的定价和折扣信息，使用户能够访问通用药物和品牌药物的优惠券和节省计划。该平台还提供价格透明工具，告知患者成本差异和可用折扣，以减轻处方药的经济负担。</p>
</div><p>In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.</p>
<div class="lb-trans"><p>除了其核心药物定价服务外，GoodRx 还在 GoodRx Care 品牌下提供远程医疗服务，为各种非紧急病症和处方需求提供虚拟咨询。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than GoodRx</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 GoodRx</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GDRX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 GDRX 吗？</strong> 访问 HoldingsChannel.com 获取 GoodRx Holdings, Inc.（NASDAQ:GDRX - 免费报告）的最新 13F 备案和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GDRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GoodRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
</div><p>Before you consider GoodRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GoodRx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
</div><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LSV 资产管理公司增加了在 GoodRx Holdings, Inc. $GDRX 的股票持仓